Circulating Oncometabolite 2-Hydroxyglutarate Is a Potential Surrogate Biomarker in Patients with Isocitrate Dehydrogenase-Mutant Intrahepatic Cholangiocarcinoma
Darrell R. Borger(Massachusetts Eye and Ear Infirmary), Andrew X. Zhu(Icahn School of Medicine at Mount Sinai), Jason E. Faris(Royal Marsden NHS Foundation Trust), Hyeryun Kim(Agios Pharmaceuticals (United States)), David P. Schenkein(Agios Pharmaceuticals (United States)), Supriya K. Saha(Diamond Harbour Women's University), Vikram Deshpande(Beth Israel Deaconess Medical Center), Kenneth K. Tanabe(Harvard University), Theodore S. Hong(Massachusetts General Hospital), Marek Ancukiewicz(Bridge University), Kimberly Straley(Agios Pharmaceuticals (United States)), Leif W. Ellisen(Harvard University), Katharine Yen(Agios Pharmaceuticals (United States)), A. John Iafrate(Massachusetts General Hospital), Lipika Goyal(Stanford Medicine), Cristina R. Ferrone(Cedars-Sinai Medical Center), Janet E. Murphy(Harvard University), Sam Agresta(Agios Pharmaceuticals (United States)), David P. Ryan(East Carolina University), Jennifer Y. Wo(Massachusetts General Hospital), Lawrence S. Blaszkowsky(Brigham and Women's Hospital), Jeffrey W. Clark(Massachusetts General Hospital), Thomas Yau(University of Hong Kong), David C. Christiani(Harvard University), Nabeel Bardeesy(Broad Institute), Ronnie T. P. Poon(Harvard University), Eunice L. Kwak(Harvard University), Hannah M. Liebman(Massachusetts General Hospital), Jill N. Allen(Harvard University), Hua Yang(China Pharmaceutical University)
Cited by 138
Related Papers
Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases
|Hepatology|2018|4.7k
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
AASLD guidelines for the treatment of hepatocellular carcinoma
|Hepatology|2017|4.2k